BT
RXRX icon

Banque Transatlantique’s Recursion Pharmaceuticals RXRX Stock Holding History

Banque Transatlantique’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.81K Hold
924
– – ﹤0.01% 407
2025
Q4 		$3.78K Hold
924
– – ﹤0.01% 232
2025
Q3 		$4.5K Hold
924
– – ﹤0.01% 228
2025
Q2 		$4.7K Hold
924
– – ﹤0.01% 216
2025
Q1 		$4.89K Hold
924
– – ﹤0.01% 202
2024
Q4 		$6.21K Buy
+924
New +$6.21K ﹤0.01% 228

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Banque Transatlantique's RXRX Position: Q1 2026 in Review

Banque Transatlantique held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 924 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #407.

Banque Transatlantique first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.21K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Banque Transatlantique held 924 shares of Recursion Pharmaceuticals worth $2.81K as of Q1 2026.
  • Banque Transatlantique left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Banque Transatlantique's portfolio in Q1 2026, its #407 holding.
  • Banque Transatlantique first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Banque Transatlantique's Recursion Pharmaceuticals position peaked at $6.21K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Banque Transatlantique's 13F filing for Q1 2026, filed 13 May 2026.